A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma

Myron S. Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M. Linton, Nina Wagner-Johnston, Randy D. Gascoyne, Graham W. Slack, Pierre Brousset, David A. Eberhard, Francisco J. Hernandez-Ilizaliturri, Gilles Salles, Thomas E. Witzig, Pier Luigi Zinzani, George W. Wright, Louis M. Staudt, Yandan Yang, P. Mickey Williams, Chih Jian Lih, Jacqueline RussoAnjan Thakurta, Patrick Hagner, Pierre Fustier, Dale Song, Ian D. Lewis

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Fingerprint Dive into the research topics of 'A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences